Basilea has announced another milestone payment from its license partner Pfizer in the Asia Pacific region and China for strong Cresemba sales. Notably, the US$2.5m milestone payment is the first of 2025 in Asia Pacific and China, and twice the value of prior milestone payments from Pfizer for this ...Den vollständigen Artikel lesen ...
© 2025 Edison Investment Research